Method for using inactivated Japanese encephalitis virus particles as adjuvant
View Patent ↗A method for using inactivated Japanese encephalitis virus particles as an adjuvant of a vaccine is provided. A method for using inactivated Japanese encephalitis virus (JEV) particles as an adjuvant of various vaccines or a mixed vaccine, said JEV particles being obtained by inoculating JEV Beijing-1 strain to Vero cells, culturing said JEV-infected cells to give cultured cells or culture supernatant, purifying JEV particles from said cultured cells or culture supernatant and inactivating said JEV particles with formalin, a method for preparing a (mixed) vaccine which comprises a step of letting inactivated Japanese encephalitis virus be contained, and a mixed vaccine prepared by said method.
1. A method for preparing a vaccine, the method comprising:
incorporating an inactivated Japanese encephalitis virus, obtained by culture of Vero cells, in the vaccine as an adjuvant wherein the inactived Japenese encephalitis virus is in particles which are present in concentration of 250 ng to 34 μg/mL, and wherein the vaccine is selected from the group consisting of diphtheria/pertussis/tetanus (DPT) vaccine, inactivated polio (IPV) vaccine, HepA vaccine and HepB vaccine.
2. The method of claim 1 , wherein the inactivated Japanese encephalitis virus has a particle structure.
3. The method of claim 2 , wherein the inactivated Japanese encephalitis virus is comprised in a concentration of 1 to 16 μg/mL.
4. The method of claim 2 , wherein the vaccine is a mixed vaccine in which two or more different vaccines are mixed together.
5. The method of claim 4 , wherein the inactivated Japanese encephalitis virus is comprised in a concentration of 1 to 16 μg/mL.
6. The method of claim 1 , wherein the vaccine is a mixed vaccine in which two or more different vaccines are mixed together.
7. The method of claim 1 , wherein the inactivated Japanese encephalitis virus is in particles which are present in a concentration of 1 to 16 μg/mL.
8. A vaccine prepared by the method of claim 7 .
9. The vaccine of claim 8 , further comprising an aluminum adjuvant.
10. A vaccine prepared by the method of claim 1 .
11. The vaccine of claim 10 , further comprising an aluminum adjuvant.
12. A method of vaccinating a subject in need thereof comprising administering to said subject an effective amount of a vaccine comprising an inactivated Japenese enecephalitis virus, obtained by a culture of Vero cells, as an adjuvant, and wherein the vaccine is selected from the group consisting of diphtheria/pertussis/tetanus (DPT) vaccine, inactivated polio (IPV) vaccine, HepA vaccine and HepB vaccine.
13. The method of claim 12 , wherein the inactivated Japenese encephalitis virus has a particle-like structure.
14. The method of claim 12 , wherein the vaccine is a mixed vaccine.
15. The method of claim 12 , wherein the inactivated Japanese encephalitis virus is in particles which are comprised in a concentration of 250 ng to 34 μg/mL.
16. The method of claim 12 , wherein the inactivated Japanese encephalitis virus is in particles which are comprised in a concentration of 1 to 16 μg/mL.